-
Breast cancer affects over 61,000 women annually in France. While only 5-10% of breast cancers are hereditary, BRCA1/2 mutations significantly increase the lifetime risk of breast and ovarian (…)
-
[...]
-
[...]
-
[...]
-
[...]
-
[...]
-
Integrating genomic medicine into healthcare systems is a health policy challenge that requires continuously transferring scientific advances into clinics and ensuring equal access for patients. (…)
-
[...]
-
[...]
-
Abstract Background Fatigue, cognitive impairment, anxiety, depression, and sleep disturbance are cancer-related behavioral symptoms that may persist years after early-stage breast cancer, (…)
-
Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent (…)
-
Breast cancer is the most common cancer diagnosed in women worldwide. Early-stage breast cancer is curable in 70-80% of patients, while advanced metastatic breast cancer is considered incurable (…)
-
Abstract Background : Long-term treatment-related toxicities, such as neurological and metabolic toxicities, are major issues in breast cancer. We investigated the interest of metabolomic (…)
-
[...]
-
This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable (…)
-
Abstract This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was (…)
-
[...]
-
[...]
-
No abstract available
-
Background and purpose :
In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric (…)
-
Abstract Background : Based on ASCENT, TROPICS-02 and DESTINY-Breast04 trials, SG and T-DXd recently became approved for HER2low MBC. Since the payloads of both SG and T-DXd belong to the same (…)
-
Abstract Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. (…)
-
En transformant les pratiques journalistiques, le numérique a surtout servi les stratégies de maximisation de l’audience des médias. Il n’est pas trop tard pour sortir de la dépendance aux Gafam.
-
Background : Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs) : Sacituzumab Govitecan (SG) and (…)
-
Introduction : The objective was to determine the added value of comprehensive molecular profile by whole‐exome and RNA sequencing (WES/RNA‐Seq) in advanced and refractory cancer patients who had (…)
-
[...]
-
[...]
-
IMPORTANCE Younger survivors of breast cancer frequently report more treatment-related symptoms, mostly related to the menopausal transition.
OBJECTIVE To assess factors associated with (…)
-
[...]
-
Background Multidrug resistance-1 (MDR1) transporter limits the intracellular accumulation of chemotherapies (paclitaxel, anthracyclines) used in breast cancer (BC) treatment. In addition to tumor (…)
-
[...]
-
[...]
-
[...]
-
Abstract Background Many patients receiving adjuvant endocrine therapy (ET) for breast cancer experience side effects and reduced quality of life (QoL) and discontinue ET. We sought to describe (…)
-
Abstract Purpose This study assessed sustainable return to work (SRTW) of breast cancer survivors (BCS). Methods We used data from the prospective French cohort, CANTO. We included 1811 stage (…)
-
Triple-negative breast cancers (TNBCs) are the most aggressive breast cancers, and therapeutic options mainly rely on chemotherapy and immunotherapy. Although synthetic glucocorticoids (GCs) are (…)
-
BackgroundEarly metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation (…)
-
Endocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERa)-positive breast cancers. However, their efficacy is (…)
-
Cette communication est centrée sur l’analyse d’une pratique d’auto-production domestique, la couture. Pratique demandant l’accumulation de savoir-faire, le rôle des plateformes numériques n’est (…)
-
Even if each rare ovarian tumor (ROT) has a low incidence, the sum of all these entities represents almost the half of all ovarian neoplasms. Thus, development of dedicated clinical trial emerged (…)
-
MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid (…)
-
Objective Splenectomy is performed in 4–32% of cytoreductive surgeries for ovarian cancer. The objective of our study was to assess splenectomy and evaluate its impact on overall and disease-free (…)
-
Cette proposition de communication est centrée sur l’analyse d’une pratique d’auto-production domestique, la couture. Pratique demandant l’accumulation de savoir-faire, le rôle des plateformes (…)
-
Background Cancer treatment is constantly evolving toward a more personalized approach based on clinical features, imaging, and genomic pathology information. To ensure the best care for patients, (…)
-
[...]
-
Abstract Background Patients with HER2-positive breast cancer (HER2 + BC) develop central nervous system metastases twice as often as patients with luminal HER2-negative breast cancer. (…)
-
[...]
-
Abstract Background The authors used the French breast cancer Cancer and Toxicities (CANTO) cohort to study the associations between baseline quality of life and chemotherapy dose‐reductions (…)
-
The local press is facing a decline in readership. However, hyperlocal information continues to circulate in regional areas. Through analysis of the different protagonists of local information (…)
-
Metastatic endocrine-resistant breast cancer (MBC) is a disease with poor prognosis and few treatment options. Low lymphocyte count is associated with limited overall survival. In a prospective (…)
Olivier Trédan